🔍

DCAL - Dishman Carbogen

📊 NSE: DCAL 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/13/2025 21:35

📢 Recent Corporate Announcements

DCAL Clarifies Credit Rating Downgrade to 'A' Despite Improving Leverage and Margins

🔵 WATCH ⭐ 7/10

REGULATORY 📅 23 Feb 2026, 07:43 PM

India Ratings & Research (IND-RA) has downgraded Dishman Carbogen Amcis Limited's (DCAL) long-term credit rating from 'A+' to 'A' and short-term rating from 'A1+' to 'A1' with a negative outlook. In response, the company issued a clarification highlighting that its financial health is actually improving, with net leverage dropping from 3.92x in March 2025 to 3.18x in September 2025. DCAL also noted that EBITDA margins for its core operations (excluding specific new sites) have reached 25.68%, which is higher than pre-EDQM observation levels. The company expects consolidated performance to strengthen as its newly re-approved Bavla site and French facility scale up.

Long-term credit rating downgraded to 'A' with a Negative outlook from 'A+' Stable.
Net leverage improved significantly to 3.18x in Sept 2025 from 3.92x in March 2025.
Net debt excluding Fx impact reduced from ₹16,164 million to ₹14,238 million in six months.
Core EBITDA margins (excluding France and India sites) rose to 25.68% in 6MFY26 vs 24.35% in FY20.
Consolidated EBITDA margins improved to 19.35% in 6MFY26 from 17.40% in FY25.

💡 Investors should closely monitor the operational ramp-up at the Bavla and French sites, as their success is key to improving the consolidated credit profile. While the rating downgrade is a negative signal, the improving leverage and core margin trends suggest the company is on a recovery path.

DCAL Subsidiary Receives GMP Compliance Certificate for Netherlands Site

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 20 Feb 2026, 07:42 PM

Dishman Carbogen Amcis Limited's wholly-owned subsidiary, CARBOGEN AMCIS B.V., has received a Certificate of GMP Compliance for its manufacturing site in Veenendaal, Netherlands. The certification was issued by the Health and Youth Care Inspectorate (IGJ), the competent authority in the Netherlands, following a successful inspection. This regulatory milestone confirms that the facility adheres to Good Manufacturing Practice standards required for pharmaceutical production. Such approvals are critical for maintaining operational continuity and serving global pharmaceutical clients from European facilities.

Wholly-owned subsidiary CARBOGEN AMCIS B.V. secured GMP compliance on February 20, 2026.
The certification specifically covers the Veenendaal site located in the Netherlands.
Approval was granted by the Health and Youth Care Inspectorate (IGJ), a key European regulator.
The compliance ensures the facility meets international quality standards for pharmaceutical manufacturing.

💡 Investors should view this as a positive development that reduces regulatory risk and supports the company's high-margin European operations. Maintain a long-term outlook as the company continues to validate its manufacturing capabilities in regulated markets.

India Ratings Downgrades DCAL to 'IND A' with Negative Outlook on High Leverage

🔴 NEGATIVE ⭐ 7/10

REGULATORY 📅 19 Feb 2026, 08:00 PM

India Ratings & Research has downgraded Dishman Carbogen Amcis Limited's (DCAL) credit rating for NCDs and bank facilities to 'IND A' with a Negative outlook. The downgrade reflects persistently high consolidated net adjusted leverage, which stood at 3.92x in FY25, and EBITDA margins that remain significantly below pre-regulatory issue levels. While the company has resolved major USFDA and EDQM issues, the ramp-up of its India CRAMS business and new French facility has been slower than anticipated. Management is planning an INR 10 billion capital raise via QIP to repay high-cost debt and target a leverage ratio below 2.5x.

Credit rating for NCDs and bank facilities downgraded to 'IND A' with a Negative outlook.
Consolidated net adjusted leverage improved to 3.92x in FY25 from 6.35x in FY24 but remains above comfort levels.
EBITDA margins for 3QFY26 fell to 15.7% compared to 22.8% in the previous year's quarter.
Robust order book of CHF 114 million for development and CHF 85 million for commercial projects as of Dec 2025.
Management intends to raise INR 10 billion through QIP or preferential shares to deleverage the balance sheet.

💡 Investors should exercise caution as the downgrade reflects stretched debt metrics; the successful execution of the proposed INR 10 billion fundraise is critical for financial stability. Monitor the ramp-up of the Bavla and French facilities for signs of EBITDA margin recovery toward the 20% mark.

DCAL Q3 FY26 Revenue Grows 5.5% to INR 720 Cr; 9M EBITDA Margins Improve to 19.4%

🔵 WATCH ⭐ 8/10

EARNINGS 📅 10 Feb 2026, 06:59 PM

Dishman Carbogen Amcis (DCAL) reported a 5.5% YoY revenue growth in Q3 FY26, reaching INR 720 crores, despite a shipment delay of INR 20 crores that shifted to January. While the quarter saw a net loss of INR 12.97 crores due to one-time refinancing costs and higher COGS from commercial supplies, the nine-month performance remains strong with a PAT of INR 75.7 crores. EBITDA margins for the nine-month period improved significantly to 19.4% from 15.9% in the previous year, driven by high-margin development revenue. The company is benefiting from lower borrowing costs in Switzerland and successful quality audits at its European facilities.

Q3 FY26 revenue reached INR 720 crores, up 5.5% YoY, despite INR 20 crores in shipments being delayed to Q4.
9M FY26 EBITDA grew 27.3% YoY to INR 403 crores, with margins expanding from 15.9% to 19.4%.
Finance costs included a one-time INR 11 crore expense for debt refinancing; however, Swiss borrowing costs have dropped to 3-3.5%.
Company successfully passed a mock FDA audit at the Vionnaz site and is progressing on a co-investment expansion project with a Japanese customer.
Employee expenses rose to INR 355 crores in Q3, including provisions for severance packages and social insurance.

💡 Investors should monitor the realization of delayed revenue in Q4 and the sustained improvement in EBITDA margins. The reduction in Swiss interest rates and successful quality audits provide a positive outlook for debt servicing and regulatory compliance.

DCAL Releases Audio Recording of Q3 FY26 Earnings Conference Call

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 04 Feb 2026, 06:12 PM

Dishman Carbogen Amcis Limited (DCAL) has officially released the audio recording of its earnings conference call held on February 4, 2025. The call was dedicated to discussing the company's financial performance and operational results for the third quarter ended December 31, 2025. This disclosure is a mandatory regulatory requirement under SEBI LODR Regulations to ensure transparency for all shareholders. Investors can access the recording on the company's investor relations portal to hear management's detailed commentary.

Audio recording of the Q3 FY26 earnings call is now available on the company website.
The conference call took place on February 4, 2025, at 15:00 hrs IST.
Discussion focused on financial results for the quarter ended December 31, 2025.
The filing covers both equity (Scrip 540701) and multiple debt instruments (975834, 976560, 977467).

💡 Investors should listen to the recording to understand management's guidance on the CRAMS business and debt levels. No immediate trading action is required based on this routine regulatory filing.

DCAL Q3 Revenue Up 5.5% to Rs 7,198 Mn; EBITDA Margins Contract to 15.7%

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 04 Feb 2026, 04:59 PM

Dishman Carbogen Amcis (DCAL) reported a modest 5.5% YoY revenue growth in Q3FY26, reaching Rs 7,198 million. However, the quarter saw a significant hit to profitability as EBITDA fell 19.3% YoY to Rs 1,131 million, with margins shrinking from 20.5% to 15.7%. This decline was primarily due to a lower contribution from high-margin late-phase III molecules in the CDMO segment. Despite the weak quarter, the 9-month performance remains positive with EBITDA up 27.3% and margins improving to 19.4% compared to the previous year.

Q3FY26 revenue increased 5.5% YoY to Rs 7,198 mn, while 9MFY26 revenue rose 4.3% to Rs 20,805 mn.
Quarterly EBITDA margins contracted to 15.7% from 20.5% in Q3FY25 due to unfavorable product mix.
CDMO segment revenue grew 6.7% YoY in Q3, but segment margins dropped from 22.1% to 16.9%.
Marketable Molecules segment revenue fell 2.4% in Q3 with margins dropping to 7.2% due to high cholesterol revenue composition.
Revenue of approximately Rs 200 million was deferred from Q3 to Q4FY26 due to supply chain delays and European holidays.

💡 Investors should be cautious of the sharp quarterly margin contraction and monitor if the deferred Rs 200 million revenue and high-margin CDMO projects recover in Q4. The long-term 9-month trend shows improvement, but the volatility in project-based CDMO margins remains a key risk.

DCAL Q3 FY26 Revenue Grows 5.5% to ₹7,198 mn; 9M PAT Turns Positive at ₹757 mn

🔵 WATCH ⭐ 7/10

EARNINGS 📅 04 Feb 2026, 02:40 PM

Dishman Carbogen Amcis (DCAL) reported a 5.5% YoY revenue growth in Q3 FY26, reaching ₹7,198 million, led by a 6.7% increase in the CDMO segment. While the company faced a net loss of ₹129.7 million in Q3 due to one-time expenses and margin contraction, the 9-month performance shows a significant turnaround with a PAT of ₹757 million compared to a loss last year. Management highlighted that ₹200 million in revenue was deferred to Q4 due to supply delays in Europe, and the company maintains a strong pipeline of 10 molecules in Late Phase III development.

Q3 FY26 Revenue rose 5.5% YoY to ₹7,198 mn, while 9M FY26 Revenue reached ₹20,805 mn.
EBITDA margins for Q3 contracted to 15.7% from 20.5% YoY, though 9M margins improved to 19.4%.
One-time costs impacted Q3, including ₹110 mn in finance expenses for new credit facilities and ₹33 mn in severance pay.
The CDMO segment remains the primary driver, contributing 87% of Q3 revenue at ₹6,297.4 mn.
Maintains a robust pipeline with 10 molecules in Late Phase III and 29 total commercialized molecules.

💡 Investors should focus on the company's ability to maintain the 9-month profitability trend and the successful commercialization of its Late Phase III pipeline. The Q3 margin dip appears driven by temporary one-off costs and revenue deferrals, making Q4 performance critical for validation.

DCAL Reports Q3 FY26 Consolidated Net Loss of ₹12.97 Cr; Operating Margins Contract to 15.71%

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 03 Feb 2026, 07:29 PM

Dishman Carbogen Amcis Limited (DCAL) reported a consolidated net loss of ₹12.97 crore for the quarter ended December 31, 2025, a sharp reversal from a profit of ₹65.27 crore in the preceding quarter. While total income from operations grew 5.5% year-on-year to ₹719.80 crore, profitability was weighed down by higher employee benefit expenses and depreciation. The operating margin saw a significant contraction to 15.71% compared to 20.61% in the year-ago period. Despite the quarterly loss, the 9-month performance remains positive with a net profit of ₹75.70 crore against a loss in the previous year.

Consolidated revenue from operations stood at ₹719.80 crore, up 5.5% YoY from ₹682.34 crore.
Reported a consolidated net loss of ₹12.97 crore for Q3 FY26 versus a profit of ₹4.63 crore in Q3 FY25.
Operating EBITDA margin contracted significantly to 15.71% from 20.61% in the same quarter last year.
Employee benefit expenses increased to ₹355.88 crore, representing nearly 49% of total income.
9-month FY26 consolidated net profit reached ₹75.70 crore, recovering from a loss of ₹39.85 crore in 9M FY25.

💡 Investors should exercise caution as the company has returned to a quarterly loss despite revenue growth, indicating pressure on margins and high fixed costs. Close monitoring of cost-rationalization measures and debt-equity levels (currently at 0.43) is advised.

DCAL Allots ₹50 Crore Senior Secured NCDs via Private Placement

🟡 NEUTRAL ⭐ 6/10

FUNDRAISE 📅 20 Jan 2026, 12:46 PM

Dishman Carbogen Amcis Limited (DCAL) has successfully allotted 5,000 Senior, Secured, Rated, Listed NCDs. The total capital raised through this private placement is ₹50 crore, with each debenture priced at ₹1,00,000. These debentures have a three-year tenure, maturing on January 20, 2029. This fundraise is part of the company's financial management strategy to secure long-term capital for its operations.

Allotment of 5,000 Senior, Secured, Rated, and Listed NCDs
Total aggregate amount raised is ₹50 crore via private placement
Face value of each debenture is ₹1,00,000 issued at par
Maturity date is set for January 20, 2029, representing a 3-year term

💡 Investors should monitor the company's debt-to-equity ratio and interest coverage to ensure the new debt remains manageable. No immediate action is required as this is a relatively small-scale fundraise for the company.

DCAL Files Quarterly Compliance Certificate Under SEBI Regulation 74(5) for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 12 Jan 2026, 03:44 PM

Dishman Carbogen Amcis Limited (DCAL) has submitted its compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by the Registrar and Share Transfer Agent (RTA) MUFG Intime India Private Limited, covers the quarter ended December 31, 2025. It confirms that all dematerialization requests were processed, and physical certificates were mutilated and cancelled within the prescribed timelines. This is a standard procedural filing required for all listed companies in India to ensure the integrity of the depository system.

Compliance certificate submitted for the quarter ended December 31, 2025.
RTA MUFG Intime India Private Limited confirmed processing of all dematerialization requests.
Securities involved in the requests are confirmed to be listed on the stock exchanges.
Physical security certificates were mutilated and cancelled after due verification by the depository participant.
The name of the depositories has been substituted in the register of members as the registered owner.

💡 No action is required as this is a routine regulatory filing. Investors should focus on the company's upcoming financial results for material performance updates.

DCAL Board Approves Rs 50 Crore NCD Issuance at 10% Coupon Rate

🟡 NEUTRAL ⭐ 6/10

FUNDRAISE 📅 27 Dec 2025, 01:01 PM

Dishman Carbogen Amcis Limited (DCAL) has approved the issuance of Senior, Secured, Rated NCDs aggregating up to Rs 50 crores on a private placement basis. The debt instruments carry a coupon rate of 10.00% per annum, with interest and principal payable on a quarterly basis. The tenure is set for 36 months, featuring a quarterly amortization schedule of 12 equal tranches. The issue is backed by a 1.1x security cover including company assets, promoter-owned land, and personal guarantees.

Issuance of up to 5,000 NCDs with a face value of Rs 1,00,000 each, totaling Rs 50 crores
Fixed coupon rate of 10.00% per annum with quarterly interest and principal payments
Tenure of 36 months with principal to be redeemed in 12 equal quarterly tranches
Security cover of 1.1x provided through company assets, promoter land, and personal guarantees
Proposed listing on the Wholesale Debt Market Segment of BSE Limited

💡 Investors should monitor the company's cash flow capacity to service the quarterly principal and interest repayments. While the fundraise amount is relatively small, the 10% interest rate reflects the current cost of debt for the company.

DCAL Board Approves Rs. 50 Crore Fundraise via Secured NCDs at 10% Coupon

🟡 NEUTRAL ⭐ 6/10

FUNDRAISE 📅 27 Dec 2025, 12:59 PM

Dishman Carbogen Amcis Limited (DCAL) has approved the issuance of Senior, Secured, Rated, Listed Non-Convertible Debentures (NCDs) totaling Rs. 50 crores. These NCDs carry a coupon rate of 10.00% per annum, with both interest and principal to be paid on a quarterly basis. The debt has a tenure of 36 months and is structured with a quarterly amortization schedule of 12 equal tranches. The issue is backed by a 1.1x security cover, including charges on specific properties and personal/corporate guarantees.

Issuance of 5,000 NCDs with a face value of Rs. 1,00,000 each, aggregating to Rs. 50 crores.
Fixed coupon rate of 10.00% per annum with a quarterly payment frequency.
Tenure of 36 months with principal repayment in 12 equal quarterly amortizing tranches.
Secured by 1.1x cover on specific immovable properties in Ahmedabad and the Naroda Plant.
Includes personal guarantee from Promoter Mr. Arpit Vyas and corporate guarantee from Dishman Infrastructure Ltd.

💡 Investors should monitor the company's quarterly cash flows to ensure they can comfortably service the high-frequency amortization and 10% interest payments. While the fundraise amount is relatively small, the structured repayment schedule requires disciplined liquidity management.

Dishman Carbogen Amcis to Close Trading Window from January 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 23 Dec 2025, 08:32 PM

Dishman Carbogen Amcis Limited (DCAL) has announced the closure of its trading window for all designated persons starting January 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the company's Q3 financial results. The window will remain closed until 48 hours after the un-audited financial results for the quarter ending December 31, 2025, are declared. This is a standard regulatory procedure for listed companies to prevent insider trading before earnings releases.

Trading window closure effective from January 1, 2026
Closure is related to the un-audited financial results for the quarter ending December 31, 2025
Applies to all Directors, Designated Persons, and their immediate relatives
Window will reopen 48 hours after the announcement of the financial results

💡 No action is required as this is a routine regulatory filing. Investors should look out for the upcoming Q3 earnings announcement to assess the company's financial health.

Dishman Carbogen Amcis Schedules Plant Visit and Analyst Meet for December 24

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 20 Dec 2025, 03:12 PM

Dishman Carbogen Amcis Limited (DCAL) has announced an in-person interaction with analysts and institutional investors scheduled for December 24, 2025. The event will take place at 15:30 hrs IST and includes a plant visit to the company's Bavla facility in Ahmedabad. This interaction is intended to provide management insights and operational visibility to the investment community. The company has clarified that no unpublished price sensitive information (UPSI) will be discussed during the session.

Analyst and investor meeting scheduled for December 24, 2025, at 15:30 hrs IST.
The interaction includes a physical plant visit at the Bavla, Ahmedabad site.
Management interaction will be conducted in-person to discuss publicly available information.
Disclosure made in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.

💡 Investors should monitor for any post-visit analyst reports or management commentary that may provide qualitative insights into the company's operational efficiency. No immediate action is required as this is a routine investor relations event.

View All DCAL Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

In H1 FY26, the CDMO segment revenue was INR 1,120.64 Cr, representing a slight degrowth of 1.1% YoY, while the Marketable Molecules (MM) segment grew significantly by 33.7% YoY to INR 240.06 Cr. For Q2 FY26, CDMO revenue was INR 509.40 Cr (-28.4% YoY) and MM was INR 143.25 Cr (+85.6% YoY).

Geographic Revenue Split

For H1 FY26, the revenue split was 55% from Europe, 25% from the United States, and 20% from Asia (predominantly Japan).

Profitability Margins

Gross margins are higher in late Phase 3 development due to extremely low material consumption compared to commercial stages. The company is seeing a substantial improvement in operating profit over the last five quarters.

EBITDA Margin

The consolidated EBITDA margin for H1 FY26 improved to 21.3% from 13.4% in H1 FY25. The CDMO segment margin rose to 25.3% in Q2 FY26 (up 632 bps YoY) driven by high-margin late Phase 3 molecules, while the MM segment margin for H1 FY26 increased to 21.4% from 9.3% YoY due to cost reduction and focus on high-margin products.

Capital Expenditure

Capital expenditure additions during Q2 FY26 were USD 7.3 million (approx. INR 61 Cr) and USD 13.3 million (approx. INR 111 Cr) for H1 FY26.

Credit Rating & Borrowing

The company successfully refinanced and enhanced its syndicated credit facilities led by UBS Switzerland AG, providing access to an additional CHF 40 million with a CHF 30 million accordion feature. Total credit capacity is CHF 162,235,250 and EUR 50,000,000.

⚙️ Operational Drivers

Raw Materials

Specific raw materials include Vitamin D analogues and Quaternary Ammonium Compounds (Quats); material consumption is noted as being significantly lower for late Phase 3 oncology molecules compared to commercial batches.

Capacity Expansion

The company is ramping up order supplies from the Bavla (India) site following three to four years of upgradations. The French facility is expected to reach profitability in FY27 as it scales toward an EBITDA breakeven.

Raw Material Costs

Raw material costs are lower for development projects (Late Phase 3) which boosts margins; the company is implementing procurement-focused cost-saving steps to improve overall efficiency.

Manufacturing Efficiency

Efficiency is improving through the 'Bavla ramp-up' and the integration of Swiss development with Indian manufacturing, allowing for faster margin growth than revenue growth.

📈 Strategic Growth

Expected Growth Rate

8-10%

Growth Strategy

Growth will be achieved by transitioning late Phase 3 molecules (including ADC and oncology) to commercial stages, ramping up the Bavla facility's output, and achieving profitability at the French facility by FY27. The company targets a total revenue of INR 3,000 Cr by FY26/FY27.

Products & Services

Contract Development and Manufacturing Services (CDMO), Oncology APIs, Antibody-Drug Conjugate (ADC) molecules, Vitamin D analogues, and Quaternary Ammonium Compounds (Quats).

Brand Portfolio

Carbogen Amcis, Dishman.

New Products/Services

Focus on ADC (Antibody-Drug Conjugates) and Bioconjugation services; late Phase 3 molecules in the oncology segment are expected to provide significant incremental revenue upon commercialization.

Market Expansion

Expansion is focused on increasing the 'integrated' business between Switzerland and India (Bavla site) and scaling the French facility.

Market Share & Ranking

Carbogen Amcis is described as a 'global top-tier' CDMO.

Strategic Alliances

Refinancing alliance with a banking syndicate led by UBS Switzerland AG.

🌍 External Factors

Industry Trends

The CDMO industry is seeing high interest in integrated service models (combining Western development with Indian manufacturing) and specialized segments like ADC and oncology, which are growing faster than standard APIs.

Competitive Landscape

Competes in the global CDMO market, specifically against other top-tier players in the high-potency API and ADC space.

Competitive Moat

The moat is built on high-containment manufacturing capabilities for oncology and ADCs, and a strong development pipeline of CHF 150 million which creates high switching costs for innovators once a molecule reaches late-stage trials.

Consumer Behavior

B2B customer behavior is shifting toward stocking larger quantities prior to product launches, leading to lumpy revenue recognition.

⚖️ Regulatory & Governance

Industry Regulations

The Bavla site was previously under 'EPM cloud' (regulatory monitoring/restrictions) for 3-4 years, during which upgradations were completed to meet international manufacturing standards.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the timeline for Phase 3 molecules to move to commercial production, which management describes as 'anybody's guess' but critical for significant revenue jumps.